

Barostimulation Publikationsliste

Hypertension / Bluthochdruck

1. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. *J Am Coll Cardiol*. 2011;58(7):765-773. doi:10.1016/j.jacc.2011.06.008.
2. Bisognano JD, Kaufman CL, Bach DS, et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos System. *J Am Coll Cardiol*. 2011;57(17):1787-1788. doi:10.1016/j.jacc.2010.11.048.
3. Alnima T, de Leeuw PW, Kroon AA. Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments. *Cardiol Res Pract*. 2012;2012:587194. doi:10.1155/2012/587194.
4. Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. *J Am Soc Hypertens*. 2012;6(4):270-276. doi:10.1016/j.jash.2012.04.004.
5. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. *J Am Soc Hypertens*. 2012;6(2):152-158. doi:10.1016/j.jash.2012.01.003.
6. Madershahian N, Scherner M, Müller-Ehmsen J, et al. Baroreflex activation therapy in patients with pre-existing implantable cardioverter-defibrillator: compatible, complementary therapies. *Europace*. 2014;16(6):861-865. doi:10.1093/europace/eut403.
7. Borisenko O, Beige J, Lovett EG, Hoppe UC, Bjessmo S. Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings. *J Hypertens*. 2014;32(3):681-692. doi:10.1097/HJH.0000000000000071.
8. Courand PY, Feugier P, Workineh S, Harbaoui B, Bricca G, Lantelme P. Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review. *Arch Cardiovasc Dis*. 2014;107(12):690-696. doi:10.1016/j.acvd.2014.08.002.
9. Wallbach M, Lehnig LY, Schroer C, et al. Impact of baroreflex activation therapy on renal function-a pilot study. *Am J Nephrol*. 2014;40(4):371-380. doi:10.1159/000368723.

10. Wachter R, Halbach M, Bakris GL, et al. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. *J Am Soc Hypertens*. 2017;11(2):81-91. doi:10.1016/j.jash.2016.12.003.
11. de Leeuw PW, Bisognano JD, Bakris GL, et al. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. *Hypertension*. 2017;69(5):836-843. doi:10.1161/HYPERTENSIONAHA.117.09086.
12. Beige J, Jentzsch T, Wendt R, Hennig G, Koziolk M, Wallbach M. Blood pressure after blinded, randomized withdrawal, and resumption of baroreceptor-activating therapy. *J Hypertens*. 2017;35(7):1496-1501. doi:10.1097/HJH.0000000000001339.
13. Wallbach M, Koziolk MJ. Baroreceptors in the carotid and hypertension-systematic review and meta-analysis of the effects of baroreflex activation therapy on blood pressure. *Nephrol Dial Transplant*. 2018;33(9):1485-1493. doi:10.1093/ndt/gfx279.
14. Wilks SJ, Hara SA, Ross EK, et al. Non-clinical and Pre-clinical Testing to Demonstrate Safety of the Barostim Neo Electrode for Activation of Carotid Baroreceptors in Chronic Human Implants. *Front Neurosci*. 2017;11:438. doi:10.3389/fnins.2017.00438.
15. Blanke CH, Willeke F, Buerke M, Darwich IA. Baroreceptor Activation Therapy 2 Decades after Vascular Surgery on Both Carotid Arteries in a Patient with Resistant Hypertension: First Case Report in the Literature. *Ann Vasc Surg*. 2018;51:326.e5-326.e8. doi:10.1016/j.avsg.2018.02.050.
16. Wallbach M, Born E, Kämpfer D, et al. Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system. *Clin Res Cardiol*. 2020;109(4):513-522. doi:10.1007/s00392-019-01536-5.
17. Wallbach M, Born E, Schäfer AK, Koziolk MJ. Effect of baroreflex activation therapy on dipping pattern in patients with resistant hypertension. *J Clin Hypertens (Greenwich)*. 2023;25(1):22-29. doi:10.1111/jch.14620.
18. Biffi A, Quarti-Trevano F, Vanoli J, et al. Effects of acute carotid baroreceptor stimulation on sympathetic nerve traffic in resistant and uncontrolled hypertension: a systematic review and meta-analysis. *Hypertens Res*. 2024;47(7):1962-1969. doi:10.1038/s41440-024-01704-9.
19. Simonsen JR, Vikatmaa L, Vikatmaa P, et al. Sham-Controlled Randomized Pilot Trial on Baroreflex Activation Therapy in Resistant Hypertension. *Hypertension*. 2024;81(8):e91-e93. doi:10.1161/HYPERTENSIONAHA.124.23088.

20. Gordin D, Simonsen R, Tikkanen I. A sham-controlled randomised pilot trial on baroreflex activation therapy in patients with resistant hypertension: What will the future hold?. *Blood Press*. 2024;33(1):2417887. doi:10.1080/08037051.2024.2417887.
21. Jordan J, Tank J, Heusser K, Reuter H. Baroreflex activation therapy through electrical carotid sinus stimulation. *Auton Neurosci*. 2024;256:103219. doi:10.1016/j.autneu.2024.103219.
22. Bustos-Merlo A, Rico-López D, Jaén-Águila F, López-Espada C, Rodríguez-Macías MI, Mediavilla-García JD. Real-world efficacy and safety of baroreceptor activation therapy in a series of patients with refractory arterial hypertension. *Hipertens Riesgo Vasc*. 2025;42(2):67-71. doi:10.1016/j.hipert.2024.10.004.
23. Kayir I, Italia T, Gajjar AA, et al. Efficacy of carotid devices for resistant hypertension: a systematic review. *J Neurointerv Surg*. Published online January 6, 2026. doi:10.1136/jnis-2025-024292.
24. Kaufeld J, Younes R, Aper T, Schmidt BMW, Menne J. Long-term efficacy and safety of first- and second-generation baroreflex activation devices in refractory hypertension: a single center retrospective analysis. *Blood Press*. 2026;35(1):2629644. doi:10.1080/08037051.2026.2629644.
25. Ernst L, Wallbach M, Zander W, et al. Effect of baroreflex activation therapy on home blood pressure measurements after long-term treatment - a prospective, randomized crossover study. *J Hypertens*. 2026;44(7):1123-1128. doi:10.1097/HJH.0000000000004270.
26. Schäfer AC, Wallbach M, Schroer C, et al. Effects of baroreflex activation therapy on cardiac function and morphology. *ESC Heart Fail*. 2024;11(5):3360-3367. doi:10.1002/ehf2.14940.

Heart Failure / Herzinsuffizienz

27. Gronda E, Seravalle G, Brambilla G, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. *Eur J Heart Fail*. 2014;16(9):977-983. doi:10.1002/ejhf.138.
28. Halbach M, Hickethier T, Madershahian N, Müller-Ehmsen J. Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction. *Expert Rev Cardiovasc Ther*. 2014;12(12):1465-1469. doi:10.1586/14779072.2014.979790.

29. Zile MR, Abraham WT, Weaver FA, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. *Eur J Heart Fail.* 2015;17(10):1066-1074. doi:10.1002/ehf.299.
30. Abraham WT, Zile MR, Weaver FA, et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. *JACC Heart Fail.* 2015;3(6):487-496. doi:10.1016/j.jchf.2015.02.006.
31. Weaver FA, Abraham WT, Little WC, et al. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. *Semin Thorac Cardiovasc Surg.* 2016;28(2):320-328. doi:10.1053/j.semtcvs.2016.04.017.
32. Gronda E, Francis D, Zannad F, Hamm C, Brugada J, Vanoli E. Baroreflex activation therapy: a new approach to the management of advanced heart failure with reduced ejection fraction. *J Cardiovasc Med (Hagerstown).* 2017;18(9):641-649. doi:10.2459/JCM.0000000000000544.
33. Dell'Oro R, Gronda E, Seravalle G, et al. Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report. *J Hypertens.* 2017;35(12):2532-2536. doi:10.1097/HJH.0000000000001498.
34. Zeitler EP, Abraham WT. Novel Devices in Heart Failure: BAT, Atrial Shunts, and Phrenic Nerve Stimulation. *JACC Heart Fail.* 2020;8(4):251-264. doi:10.1016/j.jchf.2019.11.006.
35. Januzzi JL Jr, Ibrahim NE. The Need to Innovate and Accelerate Clinical Trial Performance: BeAT the Clock. *J Am Coll Cardiol.* 2020;76(1):14-16. doi:10.1016/j.jacc.2020.05.036.
36. Robles-Mezcua A, Villaescusa-Catalán JM, Melero-Tejedor JM, García-Pinilla JM. A new approach to the treatment of advanced heart failure: a case report. *Eur Heart J Case Rep.* 2021;5(2):ytaa541. doi:10.1093/ehjcr/ytaa541.
37. Zile MR, Lindenfeld J, Weaver FA, et al. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol.* 2020;76(1):1-13. doi:10.1016/j.jacc.2020.05.015.
38. Lindenfeld J, Gupta R, Grazette L, et al. Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure. *JACC Heart Fail.* 2021;9(6):430-438. doi:10.1016/j.jchf.2021.01.012.
39. Coats AJS, Abraham WT, Zile MR, et al. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. *Eur J Heart Fail.* 2022;24(9):1665-1673. doi:10.1002/ehf.2573.

40. Duncker D, Bauersachs J. Current and future use of neuromodulation in heart failure. *Eur Heart J Suppl.* 2022;24(Suppl E):E28-E34. doi:10.1093/eurheartjsupp/suac031.
41. Guckel D, Eitz T, El Hamriti M, et al. Baroreflex activation therapy in advanced heart failure therapy: insights from a real-world scenario. *ESC Heart Fail.* 2023;10(1):284-294. doi:10.1002/ehf2.14190.
42. Schäfer AC, Müller D, Born E, et al. Impact of medication adherence on the efficacy of Baroreflex activation therapy. *J Clin Hypertens (Greenwich).* 2022;24(8):1051-1058. doi:10.1111/jch.14540.
43. Dusi V, Angelini F, Zile MR, De Ferrari GM. Neuromodulation devices for heart failure. *Eur Heart J Suppl.* 2022;24(Suppl E):E12-E27. doi:10.1093/eurheartjsupp/suac036.
44. Zannad F. Neuromodulation in heart failure. *Eur Heart J Suppl.* 2022;24(suppl E):E1-E3. doi:10.1093/eurheartjsupp/suac032.
45. Wang D, Veltmann C, Bauersachs J, Duncker D. Antiarrhythmic effects of baroreceptor activation therapy in chronic heart failure: a case report. *Eur Heart J Case Rep.* 2023;7(11):ytad520. doi:10.1093/ehjcr/ytad520.
46. Blanco C, Madej T, Mangner N, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience. *ESC Heart Fail.* 2023;10(6):3373-3384. doi:10.1002/ehf2.14508.
47. Zile MR, Lindenfeld J, Weaver FA, et al. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes. *Eur J Heart Fail.* 2024;26(4):1051-1061. doi:10.1002/ehf.3232.
48. Schäfer AC, Wallbach M, Schroer C, et al. Effects of baroreflex activation therapy on cardiac function and morphology. *ESC Heart Fail.* 2024;11(5):3360-3367. doi:10.1002/ehf2.14940.
49. Shi R, Sun T, Wang M, et al. Baroreflex activation therapy for heart failure with reduced ejection fraction: A comprehensive systematic review and meta-analysis. *Heliyon.* 2024;10(2):e24177. doi:10.1016/j.heliyon.2024.e24177.
50. Sears SF, Jordan E, Lindenfeld J, et al. Long-Term Quality of Life Response Observed in the Baroreflex Activation Therapy for Heart Failure Trial. *JACC Heart Fail.* 2024;12(12):2110-2112. doi:10.1016/j.jchf.2024.07.013.
51. Chow CY, Montoya C, Sussman M, et al. Early experience with baroreflex activation therapy from a vascular surgery perspective. *J Vasc Surg Cases Innov Tech.* 2024;10(6):101464. doi:10.1016/j.jvscit.2024.101464.
52. Tseng PT, Zeng BY, Hsu CW, et al. Network meta-analysis on efficacy of nerve stimulation or modulation in patients with heart failure. *Heart Rhythm.* 2026;23(3):623-631. doi:10.1016/j.hrthm.2025.04.004.

53. Wang D, Mueller-Leisse J, Hillmann HAK, et al. Baroreflex activation therapy in advanced heart failure: A long-term follow-up. *ESC Heart Fail.* 2025;12(1):166-173. doi:10.1002/ehf2.15104.
54. Abraham J, Bindra AS, Fudim M, et al. Real-World Analysis of Health Care Utilization With Baroreflex Activation Therapy for Heart Failure. *J Card Fail.* 2025;31(8):1349-1353. doi:10.1016/j.cardfail.2025.02.003.
55. Alhasan F, Hoffmann M, Wendell M, et al. Improved Cardiac Structure and Ventricular-Arterial Coupling After Baroreflex Activation Therapy. *JACC Case Rep.* 2025;30(32):105351. doi:10.1016/j.jaccas.2025.105351.
56. Bekiaridou A, Coleman K, Nguyen N, et al. Baroreflex activation therapy in HFrEF patients: anti-inflammatory effects and autonomic restoration. *JACC Case Rep.* 2026;31(23):108309. doi:10.1016/j.jaccas.2026.108309.
57. Basu-Ray I, Daniel RA, Saha SA, et al. Comparative efficacy of baroreflex activation therapy, cardiac contractility modulation, and cardiac resynchronization therapy in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of randomized controlled trials. *Curr Probl Cardiol.* 2026;51(10):103331. doi:10.1016/j.cpcardiol.2026.103331.
58. Nenadic I, Fudim M. Beyond Autonomic Modulation: Baroreflex Activation Therapy and the Neuroimmune Axis in HFrEF. *JACC Case Rep.* 2026;31(23):108585. doi:10.1016/j.jaccas.2026.108585.
59. Sheikh FH, Abraham WT, Adamson PB, et al. Baroreflex activation therapy in heart failure-the Barostim-Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) trial rationale and design. *J Card Fail.* Published online 2026. doi:10.1016/j.cardfail.2026.04.023.
60. Khanna NR, DenDulk A, Atteya G, Talati SN. Baroreflex Activation Therapy in a Patient With Transthyretin Amyloid Cardiomyopathy. *JACC Case Rep.* 2026;31(14):107148. doi:10.1016/j.jaccas.2026.107148.
61. Tessema FA, Grinstein J, Burkhoff D, Belkin MN. Baroreflex activation therapy invasive hemodynamic "reverse ramp" titration. *JSCAI.* 2026;5(4):104400. doi:10.1016/j.jscai.2026.104400.
62. Letarte LA, Raje V, Feliberti JP, et al. Beyond GDMT: bridging the therapeutic gap in heart failure. *Heart Fail Rev.* 2025;30(5):855-868. doi:10.1007/s10741-025-10512-3.
63. Fudim M, Yaranov DM, Gupta R, et al. Heart Failure Devices: Treatment Options, Underutilization, and a Proposed Trigger System for Patient Referral and Evaluation. *J Card Fail.* Published online September 26, 2025. doi:10.1016/j.cardfail.2025.08.019.

64. Raval YB, Pachon RE, Kenigsberg DN. Impact of baroreflex activation on medical therapy optimization in heart failure: A single-center experience with electrophysiologist-led program. *J Interv Card Electrophysiol*. Published online January 5, 2026. doi:10.1007/s10840-025-02202-9.
65. Aigbe E, Mundhra G, Egbo M, Hu YL. Baroreflex Activation Therapy and Subcutaneous ICDs: A Manageable Electrical Mismatch. *JACC Case Rep*. 2026;31(8):106652. doi:10.1016/j.jaccas.2025.106652.

Sonstiges

66. Burgoyne S, Georgakopoulos D, Belenkie I, Tyberg JV. Systemic vascular effects of acute electrical baroreflex stimulation. *Am J Physiol Heart Circ Physiol*. 2014;307(2):H236-H241. doi:10.1152/ajpheart.00422.2013.
67. Wang J, Chen J, Shu L, et al. Carotid baroreceptor stimulation improves pulmonary arterial remodeling and right ventricular dysfunction in pulmonary arterial hypertension. *JACC Basic Transl Sci*. 2024;9(4):475-492. doi:10.1016/j.jacbts.2024.01.012.